Abaxis, Inc. Announces Appointment Of Christopher Bernard To Vice President Of Marketing And Sales For Medical Market
UNION CITY, Calif., Nov. 8 /PRNewswire-FirstCall/ -- ABAXIS, Inc. , a medical products company manufacturing point-of-care blood analysis systems, announced today that it has appointed Christopher M. Bernard to the position of vice president of marketing and sales for the domestic medical market, effective immediately. Mr. Bernard succeeds Mr. Lucien Ramondetta, who has resigned his position to pursue other opportunities.
Mr. Benard joins Abaxis after a very successful 10-year tenure at Cytyc Corporation . For the past five years, Mr. Bernard served as a regional business director for Cytyc directing a staff of 52 sales professionals; driving sales from under $20 million in 2000 to more than $51 million in 2004; a compounded annual growth rate of approximately 40 percent. Prior to that, Mr. Bernard held various positions including: regional sales manager/laboratory, cytology applications manager and cytology applications specialist. Cytyc is a leading women's health company that designs, develops, manufactures, and markets innovative and clinically effective products for cervical cancer screening, breast cancer risk assessment, excessive menstrual bleeding and treatment of breast cancer.
Mr. Bernard holds a Bachelor of Science in Psychobiology from Hiram College and is an alumnus of St. Elizabeth School of Cytotechnology.
Clint Severson, Chairman, President and CEO of Abaxis, Inc. said, "We are pleased to welcome Chris Bernard to Abaxis. Chris has an extensive background in managing sales initiatives, and staff, in the placement of testing instruments in all types of medical facilities. He has a strong understanding of the role of outsourced laboratories in the medical assessment process that will be instrumental in helping Abaxis to expand the penetration of our products into the medical market. We are fortunate to add his extensive skill set to our sales and marketing team."
Mr. Severson continued, "I would also like to thank Lou Ramondetta for his dedication and leadership during his tenure and we wish him the best in the future."
ABAXIS develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 6.9 kilogram (15 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 14 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.
This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ABAXIS claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may", "believes", "projects", "expects", or "anticipates", and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to fluctuations in the Company's share price, the market acceptance of the Company's products and the continuing development of its products, required United States Food and Drug Administration ("FDA") clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the Company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks involved in carrying of inventory, risks associated with the ability to attract, train and retain competent sales personnel, general market conditions, competition and other risks detailed from time to time in ABAXIS' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. ABAXIS does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Contact: Clint Severson The RCG Group Chief Executive Officer Joe Dorame, Robert Blum, Joe Diaz ABAXIS, Inc. 480-675-0400 510-675-6500ABAXIS, Inc.
CONTACT: Clint Severson, Chief Executive Officer of ABAXIS, Inc.,+1-510-675-6500; or Joe Dorame, or Robert Blum, or Joe Diaz, all of The RCGGroup, +1-480-675-0400, for ABAXIS, Inc.